Sangamo Therapeutics, Inc.
ENGINEERED TARGET SPECIFIC NUCLEASES

Last updated:

Abstract:

Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.

Status:
Application
Type:

Utility

Filling date:

30 Sep 2020

Issue date:

28 Jan 2021